English
Choose your country/region and language
Your experience may change as only information for the country or region you select will be presented.
Why Attend IDWeek?
Emerging antimicrobial resistance (AMR) is rising globally, directly responsible for at least 1.27 million deaths and associated with nearly 5 million deaths each year.¹ Antibiotic susceptibility testing plays a crucial role in the patient treatment journey. Join leading experts, explore cutting-edge research, and network with peers in a dynamic setting in Washington, D.C.
- Centers for Disease Control and Prevention. Antimicrobial resistance facts and stats. Updated February 4, 2025. Accessed April 24, 2026. https://www.cdc.gov/antimicrobial-resistance/data-research/facts-stats/index.html
What’s Next in Diagnostics?
Visit booth 1643, where Beckman Coulter Diagnostics and Cepheid come together as part of Danaher to showcase how innovation moves from lab to life, accelerating meaningful impact for healthcare systems and patients.
Connect with peers, join expert led talks and symposia, and book time with our team to learn about the latest advancements in diagnostics.
All
Explore Solutions for Combatting AMR
Through our expertise and strategic partnerships, we are pushing boundaries with next-generation technologies to improve workflow and drive confidence in patient results. Our gold-standard accuracy helps laboratories stay ahead of rising demands. Preview our solutions below.
Our growing portfolio of infectious disease immunoassays is designed to support your HIV, syphilis, and hepatitis testing needs.
Run on our highly sensitive DxI 9000 and Access 2 immunoassay analyzers, these high-throughput laboratory assays provide information to diagnose and monitor infectious diseases.
Decoding the Host Response to Infection Requires Comprehensive, Accessible Solutions
MeMed’s host response technology decodes the complex signals of our immune system into actionable insights, to transform the way infectious diseases are diagnosed and treated.
Introducing MeMed BV Bacterial Viral Immunoassay Test
With rapid, accurate host response information to differentiate between bacterial and viral infections, MeMed BV is decoding the body’s response to infection, helping clinicians make faster, more informed decisions.
Scalable Immunoassay Solutions to Match Your Lab
The Access MeMed BV assay is now CE-marked and available in certain countries* for use on Beckman Coulter’s DxI 9000 and Access 2 immunoassay analyzers.
*Pending clearance by the United States Food and Drug Administration, not yet available for diagnostic use in the US.
*The MeMed Key is FDA 510(k)-cleared, CE-marked, and licensed by Health Canada.
Get Ready to Explore
Discover all that Washington, D.C. has to offer at IDWeek 2026
Educational Resources
Request a Meeting
Don't miss out on the latest innovations! Request a meting with our team to get hands-on experience with our cutting-edge solutions.
Complete the form below and a member of our team will reach out to you soon.
Thank you for your request. A Beckman Coulter representative will contact you shortly.
2026-15399
